Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
D000818:Animals; D002374:Catalase / Q000096:biosynthesis; D002994:Clofibrate / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007982:Levulinic Acids / Q000378:metabolism; D008099:Liver / Q000033:anatomy & histology / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D008830:Microbodies / Q000187:drug effects; D008854:Microscopy, Electron; D009255:Nafenopin / Q000494:pharmacology; D009929:Organ Size; D009940:Organoids / Q000187:drug effects*; D011233:Precipitin Tests; D011422:Propionates / Q000494:pharmacology*; D011817:Rabbits / Q000276:immunology; D051381:Rats; D011916:Rats, Inbred F344; D014316:Tritium
D000960:Hypolipidemic Agents; D007982:Levulinic Acids; D011422:Propionates; D009255:Nafenopin; D014316:Tritium; D002374:Catalase; D002994:Clofibrate